Skip to Content
Merck
CN

Z0502

Sigma-Aldrich

Zaleplon

≥98% (HPLC), solid

Synonym(s):

CL-284846, N-[3-(3-Cyanopyrazolo-[1,5-a]pyrimidin-7-yl)phenyl)-N-ethylacetamide

Sign Into View Organizational & Contract Pricing

About This Item

Empirical Formula (Hill Notation):
C17H15N5O
CAS Number:
151319-34-5
Molecular Weight:
305.33
MDL number:
MFCD00867990
UNSPSC Code:
12352200
PubChem Substance ID:
329831599

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Assay

≥98% (HPLC)

form

solid

drug control

USDEA Schedule IV; psychotrope (France); regulated under CDSA - not available from Sigma-Aldrich Canada

storage condition

desiccated
protect from light

color

white

solubility

DMSO: ~20 mg/mL
H2O: insoluble

storage temp.

2-8°C

SMILES string

CCN(C(C)=O)c1cccc(c1)-c2ccnc3c(cnn23)C#N

InChI

1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3

InChI key

HUNXMJYCHXQEGX-UHFFFAOYSA-N

Gene Information

human ... GABRA1(2554), GABRB1(2560), GABRG2(2566)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Zaleplon is a non-benzodiazepine agonist at the benzodiazepine site of the GABAA receptor; sedative; hypnotic.

Features and Benefits

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the GABAA Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Warning

Hazard Statements

H336,H361f

Hazard Classifications

Repr. 2 - STOT SE 3

Target Organs

Central nervous system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

监管及禁止进口产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
018K4711V
018K4711

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

K W Weitzel et al.
Clinical therapeutics, 22(11), 1254-1267 (2000-12-16)
Insomnia is the subjective complaint of poor sleep or an inadequate amount of sleep that adversely affects daily functioning. For the past 4 decades, treatment of insomnia has shifted away from the use of barbiturates toward the use of hypnotic
M Dooley et al.
Drugs, 60(2), 413-445 (2000-09-13)
Zaleplon is a pyrazolopyrimidine hypnotic agent which is indicated for the short term (2 to 4 weeks) management of insomnia. Zaleplon 5 and 10 mg at bedtime (usual recommended doses) significantly reduced sleep latency compared with placebo in clinical trials
Ane Birgitte Telén Andersen et al.
Pharmacoepidemiology and drug safety, 20(4), 378-385 (2011-01-25)
To estimate the degree of long-term use of zopiclone, zolpidem and zaleplon among Danes aged 65 and older and the association with sociodemographic factors and use of other drugs. Danish register-based study of 5000 men and 5000 women aged 65
Birgitta Norstedt Wikner et al.
Journal of clinical psychopharmacology, 31(3), 356-359 (2011-04-22)
Hypnotic benzodiazepine receptor agonists (HBRAs; zolpidem, zopiclone, and zaleplon) are used in the treatment of insomnia. Little is known about the safety of HBRAs during pregnancy. Data from the Swedish Medical Birth Registry from July 1, 1995, up to 2007
Joseph Barbera et al.
Drug safety, 28(4), 301-318 (2005-03-24)
Insomnia is a heterogeneous, highly prevalent condition that is associated with a high level of psychiatric, physical, social and economic morbidity. The treatment of insomnia involves pharmacological and non-pharmacological interventions. The mainstay of pharmacological treatment of insomnia has been the
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service